Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Boston Keratoprosthesis Retention in SJS/TENS
NCT01256489Phase 2Withdrawn
- Sponsor
- Massachusetts Eye and Ear
- Start
- Dec 2010
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), sponsored by Massachusetts Eye and Ear. Planned start Dec 2010; status: withdrawn.
02
Drugs
infliximab
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT01256489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256489.